enGene Therapeutics Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | 31.9% | 31.9% | -102.3% |
| FY2023 | -137.8% | -137.8% | -114.9% |
| FY2024 | -20.2% | -20.2% | -17.7% |
| FY2025 | -69.9% | -69.9% | -53.0% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | 31.9% | 31.9% | -102.3% |
| FY2023 | -137.8% | -137.8% | -114.9% |
| FY2024 | -20.2% | -20.2% | -17.7% |
| FY2025 | -69.9% | -69.9% | -53.0% |